Tyrosine Kinase Inhibitors Explained

The drugs Imatinib, Dasatinib, Nilotinib, and Ponatinib all belong to the class of medications known as Tyrosine Kinase Inhibitors (TKIs).

Mechanism of Tyrosine Kinase Inhibitors

• Tyrosine kinases are enzymes crucial for cell signaling pathways that regulate cell growth, differentiation, and survival.
• In certain cancers, specific tyrosine kinases become abnormally active, driving uncontrolled cell proliferation.
• Tyrosine Kinase Inhibitors work by blocking the activity of these specific, often mutated, tyrosine kinases.
• By inhibiting these enzymes, TKIs help to slow down or stop the growth of cancer cells.

Specific Drug Examples

Imatinib, Dasatinib, Nilotinib, and Ponatinib are specifically designed to target key tyrosine kinases involved in conditions like Chronic Myeloid Leukemia (CML) and gastrointestinal stromal tumors (GIST), making them vital examples of targeted therapy.

Drug Class Confirmation

Therefore, the correct classification for Imatinib, Dasatinib, Nilotinib, and Ponatinib is Tyrosine Kinase Inhibitors.